- Home
- SKWD vs IMNM Comparison
SKWD vs IMNM Comparison
Compare SKWD & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SKWD | IMNM |
|---|---|---|
| Founded | 2007 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 2.8B |
| IPO Year | 2022 | 2020 |
Fundamental Metrics
Financial Performance| Metric | SKWD | IMNM |
|---|---|---|
| Price | $48.57 | $22.62 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 10 |
| Target Price | ★ $64.80 | $32.10 |
| AVG Volume (30 Days) | 538.2K | ★ 959.3K |
| Earning Date | 05-25-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 41.81 | ★ 51.40 |
| EPS | ★ 4.07 | N/A |
| Revenue | ★ $1,416,541,000.00 | $6,941,000.00 |
| Revenue This Year | $31.66 | N/A |
| Revenue Next Year | $13.67 | $11.91 |
| P/E Ratio | $11.87 | ★ N/A |
| Revenue Growth | ★ 23.16 | N/A |
| 52 Week Low | $42.45 | $5.15 |
| 52 Week High | $65.05 | $27.65 |
Technical Indicators
Market Signals| Indicator | SKWD | IMNM |
|---|---|---|
| Relative Strength Index (RSI) | 59.46 | 49.44 |
| Support Level | $43.94 | $18.98 |
| Resistance Level | $50.44 | $27.14 |
| Average True Range (ATR) | 1.83 | 1.11 |
| MACD | 0.42 | -0.11 |
| Stochastic Oscillator | 90.42 | 45.25 |
Price Performance
Historical ComparisonAbout SKWD Skyward Specialty Insurance Group Inc.
Skyward Specialty Insurance Group Inc is a specialty insurance company that delivers commercial property and casualty products and solutions on a non-admitted and admitted basis. The firm has one reportable segment through which it offers a broad array of insurance coverages to several market niches. It operates multiple lines of business, including general liability, excess liability, professional liability, commercial auto, group accident, health, property, surety, and workers' compensation.
About IMNM Immunome Inc.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.